Skip to main content

Relay Therapeutics, Inc.

RLAY
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0001812364

In the last 90 days, Relay Therapeutics, Inc. insiders filed 0 open-market purchases and 14 sales; 259 institutions reported holding it in 13F filings for Q2 2026, worth $4.58B in total; Duquesne Family Office is the only superinvestor holding it.

Open-market trades, last 90 days

Open-market purchases (P) and sales (S) by Relay Therapeutics, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.

Open-market buys
0 filings
Open-market sells
14 filings
5 insiders, $121.7M in total
Insiders trading
5
Net value
−$121.7M
Purchases minus sales

Insider roster

Directors, officers and 10% owners who have filed a Form 4 for Relay Therapeutics, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.

Insider roster for Relay Therapeutics, Inc.
NameTitleLast reported holdingLast filingFilings, past year
Bergstrom Donald APresident, R&D399,130Sep 9, 20268
Catinazzo ThomasChief Financial Officer122,851Sep 9, 202612
Patel SanjivPresident and CEO519,500Sep 9, 20266
Rahmer PeterSee remarks223,657Aug 28, 20267
SB Investment Advisers (UK) Ltd10% Owner21,904,963IndirectAug 28, 20261
Softbank Vision Fund (Aiv M2) L.P.10% Owner21,904,963IndirectAug 28, 20261
SVF Pauling (Cayman) Ltd10% Owner21,904,963IndirectAug 28, 20261
Hill Linda ADirector–Jun 10, 20261
Ingram Douglas SDirector–Jun 10, 20261
Borisy AlexisDirector–Jun 10, 20261
Coats LonnelDirector–Jun 10, 20262
Dable Habib JDirector–Jun 10, 20262
Murcko MarkDirector996,952Jun 10, 20261
Mazumdar ClaireDirector–Jun 10, 20261
Adams BrianChief Legal Officer371,472Jul 30, 20250
Rubin JamiDirector67,242Jun 6, 20250
Kathiresan SekarDirector–Jun 6, 20250
Shawver LauraDirector40,000Jun 5, 20240
Porter AndyChief Administrative Officer45,164Nov 1, 20220

Insider trades

Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Oct 30, 2025 (view filing)Oct 282 daysCatinazzo ThomasChief Financial OfficerSSale−21.7K$7.29−$157.9K−6.5%313.6K after
Oct 30, 2025 (view filing)Oct 28-292 daysRahmer PeterSee remarksSSale−40.5K$7.40−$299.9K−10.7%337.5K after2 lots
Nov 4, 2025 (view filing)Nov 31 dayPatel SanjivPresident and CEOSSale−62.1K$7.00−$434.5K−8.1%703.2K after
Jan 7, 2026 (view filing)Jan 61 dayPatel SanjivPresident and CEOSSale−43.2K$7.82−$337.6K−6.1%661.0K after
Jan 29, 2026 (view filing)Jan 27-282 daysCatinazzo ThomasChief Financial OfficerSSale−15.5K$7.71−$119.6K−5.9%249.3K after2 lots
Jan 29, 2026 (view filing)Jan 27-282 daysRahmer PeterSee remarksSSale−13.0K$7.71−$100.5K−4.5%276.6K after2 lots
Jan 29, 2026 (view filing)Jan 27-282 daysBergstrom Donald APresident, R&DSSale−21.6K$7.72−$166.7K−4.9%420.0K after2 lots
Mar 11, 2026 (view filing)Mar 92 daysCatinazzo ThomasChief Financial OfficerSSale−17.7K$10.06−$178.2K−7.1%231.6K after10b5-1
Apr 9, 2026 (view filing)Apr 7-92 daysCatinazzo ThomasChief Financial OfficerSSale−19.5K$13.19−$257.5K−8.4%213.9K after2 lots10b5-1
Apr 30, 2026 (view filing)Apr 282 daysBergstrom Donald APresident, R&DSSale−1.49K$14.79−$22.0K−0.4%418.6K after
Apr 30, 2026 (view filing)Apr 282 daysRahmer PeterSee remarksSSale−753$14.79−$11.1K−0.3%275.9K after
Apr 30, 2026 (view filing)Apr 282 daysCatinazzo ThomasChief Financial OfficerSSale−972$14.79−$14.4K−0.5%212.9K after
May 14, 2026 (view filing)May 14Same dayCatinazzo ThomasChief Financial OfficerSSale−17.7K$12.86−$227.8K−8.3%195.2K after10b5-1
Jun 24, 2026 (view filing)Jun 222 daysBergstrom Donald APresident, R&DSSale−93.5K$16.94−$1.58M−18.3%418.6K after10b5-1
Jun 24, 2026 (view filing)Jun 222 daysCatinazzo ThomasChief Financial OfficerSSale−187.2K$16.97−$3.18M−51.3%177.5K after4 lots10b5-1
Jul 2, 2026 (view filing)4:12 PM ETJun 302 daysRahmer PeterSee remarksSSale−50.0K$19.09−$954.5K−18.1%225.9K after10b5-1
Jul 8, 2026 (view filing)5:07 PM ETJul 62 daysCatinazzo ThomasChief Financial OfficerSSale−17.7K$18.69−$331.1K−10.0%159.7K after10b5-1
Jul 8, 2026 (view filing)5:08 PM ETJul 71 dayPatel SanjivPresident and CEOSSale−48.2K$19.58−$943.7K−7.3%615.9K after10b5-1
Jul 8, 2026 (view filing)5:11 PM ETJul 62 daysBergstrom Donald APresident, R&DSSale−8.66K$18.71−$162.0K−2.1%409.9K after10b5-1
Jul 30, 2026 (view filing)4:12 PM ETJul 282 daysBergstrom Donald APresident, R&DSSale−2.24K$18.61−$41.6K−0.5%407.7K after
Jul 30, 2026 (view filing)4:13 PM ETJul 282 daysRahmer PeterSee remarksSSale−748$18.61−$13.9K−0.3%228.2K after
Jul 30, 2026 (view filing)4:13 PM ETJul 282 daysCatinazzo ThomasChief Financial OfficerSSale−1.46K$18.61−$27.2K−0.9%158.3K after
Aug 18, 2026 (view filing)4:16 PM ETAug 144 daysCatinazzo ThomasChief Financial OfficerSSale−17.7K$19.74−$349.7K−11.2%140.6K after10b5-1
Aug 18, 2026 (view filing)4:17 PM ETAug 171 dayPatel SanjivPresident and CEOSSale−48.2K$20.33−$979.9K−7.8%567.7K after10b5-1
Aug 28, 2026 (view filing)9:01 AM ETAug 253 daysLateSB Investment Advisers (UK) Ltd and 2 others10% OwnerSSale−6.00M$19.40−$116.4M−21.5%21.9M after
Aug 28, 2026 (view filing)4:43 PM ETAug 262 daysRahmer PeterSee remarksSSale−4.51K$20.03−$90.3K−2.0%223.7K after10b5-1
Sep 9, 2026 (view filing)4:12 PM ETSep 81 dayPatel SanjivPresident and CEOSSale−48.2K$18.94−$912.9K−8.5%519.5K after10b5-1
Sep 9, 2026 (view filing)4:15 PM ETSep 81 dayCatinazzo ThomasChief Financial OfficerSSale−17.7K$18.94−$335.6K−12.6%122.9K after10b5-1
Sep 9, 2026 (view filing)4:17 PM ETSep 81 dayBergstrom Donald APresident, R&DSSale−8.53K$18.97−$161.8K−2.1%399.1K after10b5-1